Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results


2009 | 4 | 4 | 428-432

Article title

Serum levels of resistin and hsCRP in women with PCOS


Title variants

Languages of publication



Resistin has been associated with obesity and type 2 diabetes. The elevated serum resistin level in human diabetes is often associated with a pro-inflammatory milieu. In vitro data suggest that C-reactive protein (CRP) significantly increases resistin expression in cultured human PBMC, yet the relationship in vivo is largely unknown. The purpose of this study was to determine the concentrations of CRP and resistin in women with polycystic ovary syndrome (PCOS) and to clarify whether or not there are correlations between CRP and resistin levels that have not previously been studied in PCOS in the context of resistin. Serum resistin and hsCRP levels of forty-five women with PCOS were analyzed. Compared with the control group, women with PCOS had significantly higher serum concentrations of resistin (p=0.009). Women with PCOS had higher hsCRP levels compared with controls, but these differences were not statistically significant (p>0.05). There was no correlation between serum resistin and hsCRP levels (r=0.128, p=0.404). Our study suggests that resistin concentrations was not associated with hsCRP levels


Resistin   hsCRP   PCOS  










Physical description


1 - 12 - 2009
3 - 10 - 2009


  • Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Ataturk University, TR-25240, Erzurum, Turkey
  • Department of Internal Medicine, School of Medicine, Ataturk University, TR-25240, Erzurum, Turkey
  • Department of Internal Medicine, School of Medicine, Ataturk University, TR-25240, Erzurum, Turkey
  • Department of Biochemistry, School of Medicine, Ataturk University, TR-25240, Erzurum, Turkey


  • [1] Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83:3078–3082. http://dx.doi.org/10.1210/jc.83.9.3078[Crossref]
  • [2] Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89:2745–2749. http://dx.doi.org/10.1210/jc.2003-032046[Crossref]
  • [3] Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18:774–800. http://dx.doi.org/10.1210/er.18.6.774[WoS][Crossref]
  • [4] Hopkinson ZE, Sattar N, Fleming R, Greer IA. Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. Br Med J 1998;317:329–332.
  • [5] Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:48–53. http://dx.doi.org/10.1210/jc.2005-1329[Crossref]
  • [6] Steppan CM, Brown EJ, Wright CM Bhat S, Banerjee RR, Dai CY, Enders GH, Silberg DG, Wen X, Wu GD, Lazar MA. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001; 98:502–506. http://dx.doi.org/10.1073/pnas.98.2.502[Crossref]
  • [7] Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 409; 2001: 307–312. http://dx.doi.org/10.1038/35053000[Crossref]
  • [8] Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003;300:472–476. http://dx.doi.org/10.1016/S0006-291X(02)02841-3[Crossref]
  • [9] Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50:2199–2202. http://dx.doi.org/10.2337/diabetes.50.10.2199[Crossref]
  • [10] Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285:561–564. http://dx.doi.org/10.1006/bbrc.2001.5173
  • [11] Lu SC, Shieh WY, Chen CY, Hsu SC, Chen HL. Lipopolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Lett 2002;530:158–162. http://dx.doi.org/10.1016/S0014-5793(02)03450-6[Crossref]
  • [12] Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR, et al. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003; 309:286–290. http://dx.doi.org/10.1016/j.bbrc.2003.07.003[Crossref]
  • [13] Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Gosh S, Ehtesham NZ, et al. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005; 334:1092–1101. http://dx.doi.org/10.1016/j.bbrc.2005.06.202
  • [14] Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004; 1:45–52. http://dx.doi.org/10.1371/journal.pmed.0010045[Crossref]
  • [15] Clearfield MB. C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc 2005; 105: 409–416.
  • [16] Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein. Curr Probl Cardiol 2004; 29:439–493.
  • [17] Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836–843. http://dx.doi.org/10.1056/NEJM200003233421202[Crossref][WoS]
  • [18] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod 2004; 19: 41–47. http://dx.doi.org/10.1093/humrep/deh098[Crossref]
  • [19] Ukkola O. Resistin: a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol 2002; 147: 571–574. http://dx.doi.org/10.1530/eje.0.1470571[Crossref]
  • [20] Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metabol 2002; 13: 18–22. http://dx.doi.org/10.1016/S1043-2760(01)00522-7[Crossref]
  • [21] Panidis D, Koliakos G, Kourtis A, Farmakiotis D, Mouslech T, Rousso D. Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 361–365. http://dx.doi.org/10.1016/j.fertnstert.2003.06.021[Crossref]
  • [22] Kelly CC, lyall H, Petrie JR, Gould GW, Connell JM, Satar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86: 2453–2455. http://dx.doi.org/10.1210/jc.86.6.2453[Crossref]
  • [23] Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low grade chronic inflammation. J Clin Endocrinol Metab 2004; 89: 5592–5596. http://dx.doi.org/10.1210/jc.2004-0751[Crossref]
  • [24] Bickerton AS, Clarck N, Meeking D, Shaw KM, Crook M, Lumb P, Turner C and Cummings MH. Cardiovascular risk in women with polycystic ovarian syndrome. J Clin Pathol 2005; 58: 151–154. http://dx.doi.org/10.1136/jcp.2003.015271[Crossref]
  • [25] Mohlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, Schlosser HW, Brabant G and Schofl C. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004; 150:525–532. http://dx.doi.org/10.1530/eje.0.1500525[Crossref]
  • [26] Hu WL, Qian SB, Li JL. Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin. Cytokine 2007; 40:201–206. http://dx.doi.org/10.1016/j.cyto.2007.09.011[Crossref][WoS]
  • [27] Rittmaster RS, Deshwal N, Lehman L. The role of adrenal hyperandrogenism, insulin resistance and obesity in the pathogenesis of polycystic ovarian syndrome. J Clin Endocrinol Metab 1993; 76:1295–1300. http://dx.doi.org/10.1210/jc.76.5.1295[Crossref]
  • [28] Polderman KH, Gooren JG, Asscherman H, Bakker A and Heine RJ. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 1994; 79: 265–271. http://dx.doi.org/10.1210/jc.79.1.265[Crossref]
  • [29] Seow KM, Juan CH, Wu LY, Hsu YP, Yang WM, Tsai YL, Hwang JL and Ho LT. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance. Hum Reprod 2004;19: 48–53. http://dx.doi.org/10.1093/humrep/deh010[Crossref]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.